CAS: 132036-88-5 - RAMOSETRON
Formula:C17H17N3O
InChI:InChI=1S/C17H17N3O/c1-20-9-13(12-4-2-3-5-16(12)20)17(21)11-6-7-14-15(8-11)19-10-18-14/h2-5,9-11H,6-8H2,1H3,(H,18,19)/t11-/m1/s1
InChI key:InChIKey=NTHPAPBPFQJABD-LLVKDONJSA-N
SMILES:O=C(C1=CN(C=2C=CC=CC12)C)C3CC=4NC=NC4CC3
- Synonyms:
- (-)-(R)-1-Methylindol-3-yl 4,5,6,7-tetrahydro-5-benzimidazolylketone
- (1-methyl-1H-indol-3-yl)[(6R)-4,5,6,7-tetrahydro-1H-benzimidazol-6-yl]methanone
- (1-methyl-1H-indol-3-yl)[(6S)-4,5,6,7-tetrahydro-1H-benzimidazol-6-yl]methanone
- (R)-5-[(1-Methylindole-3-Yl)Carbonyl]-4,5,6,7-Tetrahydro-1H-Bezimidazole, 98+%
- Methanone, (1-methyl-1H-indol-3-yl)(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)-, (R)-
- Methanone, (1-methyl-1H-indol-3-yl)[(5R)-4,5,6,7-tetrahydro-1H-benzimidazol-5-yl]-
- Methanone, (1-methyl-1H-indol-3-yl)[(5R)-4,5,6,7-tetrahydro-1H-benzimidazol-5-yl]- (9CI)
- Methanone, (1-methyl-1H-indol-3-yl)[(6R)-4,5,6,7-tetrahydro-1H-benzimidazol-6-yl]-
- Nasea
- Nor-YM 060
- See more synonyms
Brand | Product data | Purity | Price range | Estimated delivery |
---|---|---|---|---|
Methanone, (1-methyl-1H-indol-3-yl)[(6R)-4,5,6,7-tetrahydro-1H-benzimidazol-6-yl]- REF: IN-DA001037CAS: 132036-88-5 | 98% | 59.00 €~564.00 € | Tue 07 Jan 25 | |
Ramosetron REF: TM-T4562CAS: 132036-88-5 | 98.98% | 36.00 €~152.00 € | Mon 13 Jan 25 |
Methanone, (1-methyl-1H-indol-3-yl)[(6R)-4,5,6,7-tetrahydro-1H-benzimidazol-6-yl]-
CAS:132036-88-5
Formula:
C17H17N3O
Purity:
98%
Molecular weight:
279.3364
Ref: IN-DA001037
10mg | 120.00 € | ||
25mg | 180.00 € | ||
50mg | 188.00 € | ||
100mg | 283.00 € | ||
200mg | 564.00 € |
Estimated delivery in United States, on Tuesday 7 Jan 2025
Ramosetron
CAS:132036-88-5
Ramosetron is a serotonin 5-HT3 receptor antagonist for the treatment of nausea and vomiting.
Formula:
C17H17N3O
Purity:
98.98%
Color and Shape:
Solid
Molecular weight:
279.34
Ref: TM-T4562
10mg | 36.00 € | ||
25mg | 48.00 € | ||
50mg | 76.00 € | ||
100mg | 100.00 € | ||
200mg | 152.00 € | ||
1mL*10mM (DMSO) | 36.00 € |
Estimated delivery in United States, on Monday 13 Jan 2025